| Variable . | Procedure . | Operation time . | Blood loss . | Duration of thoracic drainage (days) . | Pathological stage . | Adjuvant chemotherapy . | Follow-up duration (months) . | Recurrence-free duration (months) . | Status . |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | SPE | 190 | 1200 | 5 | T3N2M0 | 0 | 12 | 6 | Died |
| Case 2 | SPE | 150 | 100 | 7 | T4N0M0 | 5 EC | 24 | 14 | Died |
| Case 3 | SPE | 125 | 100 | 5 | T4N2M0 | 6 EP | 30 | 26 | Died |
| Case 4 | LSSCR | 280 | 250 | 6 | T4N0M0 | 0 EC | 37 | 37 | Alive |
| Case 5 | SPE | 140 | 50 | 7 | T3N0M0 | 6 EP | 36 | 36 | Alive |
| Case 6 | SPE | 235 | 100 | 3 | T3N0M0 | 0 | 24 | 24 | Alive |
| Case 7 | SCRUL | 340 | 250 | 7 | T3N0M0 | 3 EP | 23 | 23 | Alive |
| Case 8 | SPE | 175 | 600 | 2 | T2N2M0 | 1 EP | 19 | 10 | Died |
| Case 9 | SPE | 245 | 350 | 9 | T4N0M0 | 4 EP | 28 | 26 | Alive |
| Case 10 | SPE | 220 | 200 | 15 | T4N1M0 | 6 EP | 18 | 18 | Alive |
| Case 11 | SCRUL | 305 | 200 | 9 | T3N2M0 | 1 EP | 12 | 12 | Alive |
| Case 12 | SPE | 130 | 200 | 3 | T4N2M0 | 0 | 6 | 6 | Alive |
| Case 13 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 46 | 46 | Alive |
| Case 14 | SCRUL | 310 | 100 | 6 | T3N0M0 | 0 | 47 | 47 | Alive |
| Case 15 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 43 | 43 | Alive |
| Case 16 | SCRUL | 270 | 100 | 6 | T3N0M0 | 0 | 44 | 44 | Alive |
| Variable . | Procedure . | Operation time . | Blood loss . | Duration of thoracic drainage (days) . | Pathological stage . | Adjuvant chemotherapy . | Follow-up duration (months) . | Recurrence-free duration (months) . | Status . |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | SPE | 190 | 1200 | 5 | T3N2M0 | 0 | 12 | 6 | Died |
| Case 2 | SPE | 150 | 100 | 7 | T4N0M0 | 5 EC | 24 | 14 | Died |
| Case 3 | SPE | 125 | 100 | 5 | T4N2M0 | 6 EP | 30 | 26 | Died |
| Case 4 | LSSCR | 280 | 250 | 6 | T4N0M0 | 0 EC | 37 | 37 | Alive |
| Case 5 | SPE | 140 | 50 | 7 | T3N0M0 | 6 EP | 36 | 36 | Alive |
| Case 6 | SPE | 235 | 100 | 3 | T3N0M0 | 0 | 24 | 24 | Alive |
| Case 7 | SCRUL | 340 | 250 | 7 | T3N0M0 | 3 EP | 23 | 23 | Alive |
| Case 8 | SPE | 175 | 600 | 2 | T2N2M0 | 1 EP | 19 | 10 | Died |
| Case 9 | SPE | 245 | 350 | 9 | T4N0M0 | 4 EP | 28 | 26 | Alive |
| Case 10 | SPE | 220 | 200 | 15 | T4N1M0 | 6 EP | 18 | 18 | Alive |
| Case 11 | SCRUL | 305 | 200 | 9 | T3N2M0 | 1 EP | 12 | 12 | Alive |
| Case 12 | SPE | 130 | 200 | 3 | T4N2M0 | 0 | 6 | 6 | Alive |
| Case 13 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 46 | 46 | Alive |
| Case 14 | SCRUL | 310 | 100 | 6 | T3N0M0 | 0 | 47 | 47 | Alive |
| Case 15 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 43 | 43 | Alive |
| Case 16 | SCRUL | 270 | 100 | 6 | T3N0M0 | 0 | 44 | 44 | Alive |
EC: etoposide + carboplatin; EP: etoposide + paclitaxel; LSSCR: lung-sparing sleeve carinal resection; SCRUL: sleeve carinal right upper lobectomy; SPE: sleeve pneumonectomy.
| Variable . | Procedure . | Operation time . | Blood loss . | Duration of thoracic drainage (days) . | Pathological stage . | Adjuvant chemotherapy . | Follow-up duration (months) . | Recurrence-free duration (months) . | Status . |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | SPE | 190 | 1200 | 5 | T3N2M0 | 0 | 12 | 6 | Died |
| Case 2 | SPE | 150 | 100 | 7 | T4N0M0 | 5 EC | 24 | 14 | Died |
| Case 3 | SPE | 125 | 100 | 5 | T4N2M0 | 6 EP | 30 | 26 | Died |
| Case 4 | LSSCR | 280 | 250 | 6 | T4N0M0 | 0 EC | 37 | 37 | Alive |
| Case 5 | SPE | 140 | 50 | 7 | T3N0M0 | 6 EP | 36 | 36 | Alive |
| Case 6 | SPE | 235 | 100 | 3 | T3N0M0 | 0 | 24 | 24 | Alive |
| Case 7 | SCRUL | 340 | 250 | 7 | T3N0M0 | 3 EP | 23 | 23 | Alive |
| Case 8 | SPE | 175 | 600 | 2 | T2N2M0 | 1 EP | 19 | 10 | Died |
| Case 9 | SPE | 245 | 350 | 9 | T4N0M0 | 4 EP | 28 | 26 | Alive |
| Case 10 | SPE | 220 | 200 | 15 | T4N1M0 | 6 EP | 18 | 18 | Alive |
| Case 11 | SCRUL | 305 | 200 | 9 | T3N2M0 | 1 EP | 12 | 12 | Alive |
| Case 12 | SPE | 130 | 200 | 3 | T4N2M0 | 0 | 6 | 6 | Alive |
| Case 13 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 46 | 46 | Alive |
| Case 14 | SCRUL | 310 | 100 | 6 | T3N0M0 | 0 | 47 | 47 | Alive |
| Case 15 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 43 | 43 | Alive |
| Case 16 | SCRUL | 270 | 100 | 6 | T3N0M0 | 0 | 44 | 44 | Alive |
| Variable . | Procedure . | Operation time . | Blood loss . | Duration of thoracic drainage (days) . | Pathological stage . | Adjuvant chemotherapy . | Follow-up duration (months) . | Recurrence-free duration (months) . | Status . |
|---|---|---|---|---|---|---|---|---|---|
| Case 1 | SPE | 190 | 1200 | 5 | T3N2M0 | 0 | 12 | 6 | Died |
| Case 2 | SPE | 150 | 100 | 7 | T4N0M0 | 5 EC | 24 | 14 | Died |
| Case 3 | SPE | 125 | 100 | 5 | T4N2M0 | 6 EP | 30 | 26 | Died |
| Case 4 | LSSCR | 280 | 250 | 6 | T4N0M0 | 0 EC | 37 | 37 | Alive |
| Case 5 | SPE | 140 | 50 | 7 | T3N0M0 | 6 EP | 36 | 36 | Alive |
| Case 6 | SPE | 235 | 100 | 3 | T3N0M0 | 0 | 24 | 24 | Alive |
| Case 7 | SCRUL | 340 | 250 | 7 | T3N0M0 | 3 EP | 23 | 23 | Alive |
| Case 8 | SPE | 175 | 600 | 2 | T2N2M0 | 1 EP | 19 | 10 | Died |
| Case 9 | SPE | 245 | 350 | 9 | T4N0M0 | 4 EP | 28 | 26 | Alive |
| Case 10 | SPE | 220 | 200 | 15 | T4N1M0 | 6 EP | 18 | 18 | Alive |
| Case 11 | SCRUL | 305 | 200 | 9 | T3N2M0 | 1 EP | 12 | 12 | Alive |
| Case 12 | SPE | 130 | 200 | 3 | T4N2M0 | 0 | 6 | 6 | Alive |
| Case 13 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 46 | 46 | Alive |
| Case 14 | SCRUL | 310 | 100 | 6 | T3N0M0 | 0 | 47 | 47 | Alive |
| Case 15 | SPE | 220 | 150 | 4 | T4N0M0 | 3 EP | 43 | 43 | Alive |
| Case 16 | SCRUL | 270 | 100 | 6 | T3N0M0 | 0 | 44 | 44 | Alive |
EC: etoposide + carboplatin; EP: etoposide + paclitaxel; LSSCR: lung-sparing sleeve carinal resection; SCRUL: sleeve carinal right upper lobectomy; SPE: sleeve pneumonectomy.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
